Avandia, a drug used to treat type II diabetes, may receive a warning label that displays the increased risks of bone fracture found in a new study.
Two tests demonstrated a link between the drug and broken bones in the hands and feet of women. It was found that men who used the drug for longer than 16 months had lower bone mineral density in their spine and hips than before taking Avandia.
“This suggests that thiazolidinedione treatment is a risk factor and can contribute to excess incidence of fractures in diabetes,” researchers from the VA Medical Center and Louisiana State University in Shreveport, Louisiana wrote in the study.
Andrew Baum, a Morgan Stanley analyst, says that Avandia is “almost certain” to receive a new warning about the risk of fracture in women on the drug’s label. An advisory panel for the FDA is scheduled to have a meeting about Avandia on July 30. Avandia has already been linked to heart ailments in patients.
For more information on this subject, please refer to our section on Drugs, Medical Devices, and Implants.